NRAS and melanoma: Volasertib (BI 6727) had been shown to delay growth of melanoma tumors and to cause regression by inducing apoptosis in vivo [47] and, importantly, it showed synergistic antitumor effects together with the MEK inhibitor Trametinib in NRAS mutant melanoma [48].